The US Food and Drug Administration (FDA) has granted accelerated approval to Vimkunya™, a recombinant chikungunya vaccine, ...

Chikungunya, caused by the chikungunya virus (CHIKV) and spread through mosquito bites, leads to fever, rash, fatigue, headache, and severe joint pain. While rarely fatal, it can lead to long ...

If authorised, Vimkunya would be the first vaccine in the EU to protect individuals aged 12 and older against chikungunya, a mosquito-borne disease that leads to fever and joint pain. While most ...

Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8 mL dose.

As a bonus, Bavarian Nordic also gets a priority review voucher from the FDA, awarded as an incentive to carry out drug ...

The US Food and Drug Administration (FDA) has approved Bavarian Nordic’s chikungunya vaccine Vimkunya for use in individuals ...

Sri Lanka is experiencing a rise in Chikungunya cases, with the highest number of infections being reported across the country. ..

Chikungunya is an emerging global health threat ... It causes fever and debilitating joint pain – as well as muscle aches, joint swelling, headache, nausea, fatigue, and rash – and in severe ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent ...

and the Americas have confirmed the prevalence of chikungunya virus, which spreads by infected Aedes mosquitoes and causes a disease characterized by fever and joint pain, among other symptoms The ...